CervoMed Reports Second Quarter 2024 Financial Results, Provides Business Updates

– Enrollment for the RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) will be completed in June 2024; topline data are expected in December 2024 –

– In July 2024, he hosted a virtual key opinion leader event highlighting the potential of neflamapimod for patients with early-stage DLB –